Abstract
When the entire world is eagerly waiting for a safe, effective and widely available COVID-19 vaccine, un-precedented spikes of new cases are evident in numerous countries. To gain a deeper understanding about the future dynamics of COVID-19, a compartmental mathematical model has been proposed in this paper incorporating all possible non-pharmaceutical intervention policies. Model parameters have been calibrated using sophisticated trust-region-reflective algorithm and short-term projection results have been illustrated for Argentina, Bangladesh, Brazil, Colombia and India. Control reproduction numbers (ℛc) have been calculated in order to get insights about the current epidemic scenario in the above-mentioned countries. Forecasting results depict that the aforesaid countries are having downward trends in daily COVID-19 cases. However, it is highly recommended to use efficacious face coverings and maintain strict physical distancing, as the pandemic is not over in any country. Global sensitivity analysis enlightens the fact that efficacy of face coverings is the most significant parameter, which could significantly control the transmission dynamics of the novel coronavirus compared to other non-pharmaceutical measures. In addition, reduction in effective contact rate with isolated patients is also essential in bringing down the epidemic threshold (ℛc) below unity. All necessary graphical simulations have been performed with the help of Caputo-Fabrizio fractional derivatives. In addition, optimal control problem for fractional system has been designed and the existence of unique solution has also been showed by using Picard-Lindelof technique. Finally, the unconditionally stability of the given fractional numerical technique has been proved.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding is received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available online
